Cargando…

IODVA1, a guanidinobenzimidazole derivative, targets Rac activity and Ras-driven cancer models

We report the synthesis and preliminary characterization of IODVA1, a potent small molecule that is active in xenograft mouse models of Ras-driven lung and breast cancers. In an effort to inhibit oncogenic Ras signaling, we combined in silico screening with inhibition of proliferation and colony for...

Descripción completa

Detalles Bibliográficos
Autores principales: Gasilina, Anjelika, Premnauth, Gurdat, Gurjar, Purujit, Biesiada, Jacek, Hegde, Shailaja, Milewski, David, Ma, Gang, Kalin, Tanya V., Merino, Edward, Meller, Jarek, Seibel, William, Cancelas, José A., Vinnedge, Lisa Privette, Nassar, Nicolas N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7067412/
https://www.ncbi.nlm.nih.gov/pubmed/32163428
http://dx.doi.org/10.1371/journal.pone.0229801
_version_ 1783505396620591104
author Gasilina, Anjelika
Premnauth, Gurdat
Gurjar, Purujit
Biesiada, Jacek
Hegde, Shailaja
Milewski, David
Ma, Gang
Kalin, Tanya V.
Merino, Edward
Meller, Jarek
Seibel, William
Cancelas, José A.
Vinnedge, Lisa Privette
Nassar, Nicolas N.
author_facet Gasilina, Anjelika
Premnauth, Gurdat
Gurjar, Purujit
Biesiada, Jacek
Hegde, Shailaja
Milewski, David
Ma, Gang
Kalin, Tanya V.
Merino, Edward
Meller, Jarek
Seibel, William
Cancelas, José A.
Vinnedge, Lisa Privette
Nassar, Nicolas N.
author_sort Gasilina, Anjelika
collection PubMed
description We report the synthesis and preliminary characterization of IODVA1, a potent small molecule that is active in xenograft mouse models of Ras-driven lung and breast cancers. In an effort to inhibit oncogenic Ras signaling, we combined in silico screening with inhibition of proliferation and colony formation of Ras-driven cells. NSC124205 fulfilled all criteria. HPLC analysis revealed that NSC124205 was a mixture of at least three compounds, from which IODVA1 was determined to be the active component. IODVA1 decreased 2D and 3D cell proliferation, cell spreading and ruffle and lamellipodia formation through downregulation of Rac activity. IODVA1 significantly impaired xenograft tumor growth of Ras-driven cancer cells with no observable toxicity. Immuno-histochemistry analysis of tumor sections suggests that cell death occurs by increased apoptosis. Our data suggest that IODVA1 targets Rac signaling to induce death of Ras-transformed cells. Therefore, IODVA1 holds promise as an anti-tumor therapeutic agent.
format Online
Article
Text
id pubmed-7067412
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-70674122020-03-23 IODVA1, a guanidinobenzimidazole derivative, targets Rac activity and Ras-driven cancer models Gasilina, Anjelika Premnauth, Gurdat Gurjar, Purujit Biesiada, Jacek Hegde, Shailaja Milewski, David Ma, Gang Kalin, Tanya V. Merino, Edward Meller, Jarek Seibel, William Cancelas, José A. Vinnedge, Lisa Privette Nassar, Nicolas N. PLoS One Research Article We report the synthesis and preliminary characterization of IODVA1, a potent small molecule that is active in xenograft mouse models of Ras-driven lung and breast cancers. In an effort to inhibit oncogenic Ras signaling, we combined in silico screening with inhibition of proliferation and colony formation of Ras-driven cells. NSC124205 fulfilled all criteria. HPLC analysis revealed that NSC124205 was a mixture of at least three compounds, from which IODVA1 was determined to be the active component. IODVA1 decreased 2D and 3D cell proliferation, cell spreading and ruffle and lamellipodia formation through downregulation of Rac activity. IODVA1 significantly impaired xenograft tumor growth of Ras-driven cancer cells with no observable toxicity. Immuno-histochemistry analysis of tumor sections suggests that cell death occurs by increased apoptosis. Our data suggest that IODVA1 targets Rac signaling to induce death of Ras-transformed cells. Therefore, IODVA1 holds promise as an anti-tumor therapeutic agent. Public Library of Science 2020-03-12 /pmc/articles/PMC7067412/ /pubmed/32163428 http://dx.doi.org/10.1371/journal.pone.0229801 Text en © 2020 Gasilina et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Gasilina, Anjelika
Premnauth, Gurdat
Gurjar, Purujit
Biesiada, Jacek
Hegde, Shailaja
Milewski, David
Ma, Gang
Kalin, Tanya V.
Merino, Edward
Meller, Jarek
Seibel, William
Cancelas, José A.
Vinnedge, Lisa Privette
Nassar, Nicolas N.
IODVA1, a guanidinobenzimidazole derivative, targets Rac activity and Ras-driven cancer models
title IODVA1, a guanidinobenzimidazole derivative, targets Rac activity and Ras-driven cancer models
title_full IODVA1, a guanidinobenzimidazole derivative, targets Rac activity and Ras-driven cancer models
title_fullStr IODVA1, a guanidinobenzimidazole derivative, targets Rac activity and Ras-driven cancer models
title_full_unstemmed IODVA1, a guanidinobenzimidazole derivative, targets Rac activity and Ras-driven cancer models
title_short IODVA1, a guanidinobenzimidazole derivative, targets Rac activity and Ras-driven cancer models
title_sort iodva1, a guanidinobenzimidazole derivative, targets rac activity and ras-driven cancer models
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7067412/
https://www.ncbi.nlm.nih.gov/pubmed/32163428
http://dx.doi.org/10.1371/journal.pone.0229801
work_keys_str_mv AT gasilinaanjelika iodva1aguanidinobenzimidazolederivativetargetsracactivityandrasdrivencancermodels
AT premnauthgurdat iodva1aguanidinobenzimidazolederivativetargetsracactivityandrasdrivencancermodels
AT gurjarpurujit iodva1aguanidinobenzimidazolederivativetargetsracactivityandrasdrivencancermodels
AT biesiadajacek iodva1aguanidinobenzimidazolederivativetargetsracactivityandrasdrivencancermodels
AT hegdeshailaja iodva1aguanidinobenzimidazolederivativetargetsracactivityandrasdrivencancermodels
AT milewskidavid iodva1aguanidinobenzimidazolederivativetargetsracactivityandrasdrivencancermodels
AT magang iodva1aguanidinobenzimidazolederivativetargetsracactivityandrasdrivencancermodels
AT kalintanyav iodva1aguanidinobenzimidazolederivativetargetsracactivityandrasdrivencancermodels
AT merinoedward iodva1aguanidinobenzimidazolederivativetargetsracactivityandrasdrivencancermodels
AT mellerjarek iodva1aguanidinobenzimidazolederivativetargetsracactivityandrasdrivencancermodels
AT seibelwilliam iodva1aguanidinobenzimidazolederivativetargetsracactivityandrasdrivencancermodels
AT cancelasjosea iodva1aguanidinobenzimidazolederivativetargetsracactivityandrasdrivencancermodels
AT vinnedgelisaprivette iodva1aguanidinobenzimidazolederivativetargetsracactivityandrasdrivencancermodels
AT nassarnicolasn iodva1aguanidinobenzimidazolederivativetargetsracactivityandrasdrivencancermodels